DCF Valuation
Zealand Pharma A/S (ZLDPF) DCF Valuation — Is ZLDPF overvalued?
The estimated DCF fair value of one Zealand Pharma A/S (ZLDPF) share is $18.74. Compared to the current market price of $47.50, the stock is overvalued by 60.6%.
DCF fair value
$18.74
Market price
$47.50
Upside / downside
−60.6%
Prefer the inverse question? See what growth rate the market is pricing into ZLDPF →
Zealand Pharma A/S (ZLDPF) DCF valuation FAQ
What is the DCF fair value of Zealand Pharma A/S (ZLDPF)?
The discounted-cash-flow model estimates the intrinsic fair value of one Zealand Pharma A/S (ZLDPF) share at $18.74, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Zealand Pharma A/S (ZLDPF) overvalued or undervalued?
Against the current market price of $47.50, the DCF fair value of $18.74 implies ZLDPF is overvalued by 60.6%.
How is the ZLDPF DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Zealand Pharma A/S's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Zealand Pharma A/S files a new quarterly or annual report.
How this ZLDPF valuation is built
The model projects ten years of Zealand Pharma A/S's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Zealand Pharma A/S's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Zealand Pharma A/S files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-05.